Expansion opportunities Viome Life Sciences has recently expanded offices in Bothell, WA and is actively growing through acquisitions (Naring Health) and a Series C funding round, indicating a scalable operation and potential for enterprise partnerships and channel sales with larger health systems, clinics, and employer wellness programs.

At-home screening pitch The company offers an at-home RNA and gene expression test and is developing at-home RNA screening for colon cancer, presenting a clear upsell path to direct-to-consumer wellness programs, telehealth integration, and periodic subscription-based testing for preventive care.

AI driven value With a state-of-the-art AI platform analyzing large gene expression datasets to predict risk, diagnose early, and guide therapeutics, there is a strong proposition for partnerships with pharma, clinical research organizations, and payers seeking precision diagnostics and patient stratification tools.

Rapid growth potential Recent notable funding and strategic investments from Khosla Ventures, Bold Capital, and WestRiver Group, combined with an active M&A footprint, suggest Viome is in growth mode and open to enterprise deals, large-scale pilot programs, and co-development opportunities.

Complementary services Viome’s integration of microbial and human gene expression insights, along with therapeutics and prognostics under one portfolio, creates cross-sell opportunities to diagnostic labs, nutrition and wellness platforms, and corporate wellness programs seeking comprehensive preventive health solutions.